US 11510998
Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHC
granted A61KA61K47/26A61K48/0066
Quick answer
US patent 11510998 (Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHC) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K47/26, A61K48/0066, A61P, A61P43/00